← Russell 3000 cross-section

ZBH ZIMMER BIOMET HOLDINGS, INC.

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$19.2bn
Revenue TTM
$8.5bn
Net income TTM
$807m
Free cash flow
$1.5bn
Composite score
56.0
Sector rank
#461

Valuation

P / E
23.8
EV / EBITDA
10.8
EV / sales
2.9
FCF yield
7.92%
Earnings yield vs 10-yr
-0.53pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
9.5%
EBITDA margin
27.2%
ROE
6.4%
ROIC
6.5%
Revenue growth
8.6%

Insider activity, last 90 days

Net open-market
$-0.41m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

At the effective time of the acquisition, each outstanding share of Paragon 28 was automatically cancelled and retired and converted into the right to receive (i) $ 13.00 in cash and (ii) a non-tradeable contingent value right ("CVR") entitling the holder to receive up to $ 1.00 per share in cash if certain revenue milestones are achieved. The estimated fair value of this contingent consideration liability was calculated using a Black Scholes framework, utilizing strike prices at the maximum and minimum amount of the revenue that needs to be achieved to earn a payout, and discounting to present value the estimated payment. …ZIMMER BIOMET HOLDINGS, INC., 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →